Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Drops By 68.0%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 14,500 shares, a drop of 68.0% from the March 31st total of 45,300 shares. Based on an average daily trading volume, of 55,500 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the shares of the company are sold short.

Alzamend Neuro Price Performance

Shares of NASDAQ ALZN traded up $0.02 during trading hours on Friday, reaching $0.72. The stock had a trading volume of 14,435 shares, compared to its average volume of 46,123. The company has a market cap of $4.94 million, a price-to-earnings ratio of -0.74 and a beta of 0.02. The business’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.23. Alzamend Neuro has a twelve month low of $0.65 and a twelve month high of $11.91.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings data on Monday, March 25th. The company reported ($0.38) EPS for the quarter.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.